With an experienced researcher at the helm, Seoul-based Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies
CEO Soon Paik, who was a developer Oncotype Dx and the founding director of Samsung Cancer Research Institute, discusses Theragen's sequencing and bioinformatics business and how he hopes to develop cancer vaccines and targeted therapies such as against MAPK3.